%PDF-1.4
%
109 0 obj
<>
endobj
106 0 obj
<>
endobj
175 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-02-05T16:09:55Z
2024-03-28T16:17:35-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:17:35-07:00
application/pdf
Heather
2002-813.march
uuid:f2f4a059-1dd1-11b2-0a00-410827bd7700
uuid:f2f4a05b-1dd1-11b2-0a00-900000000000
endstream
endobj
95 0 obj
<>
endobj
96 0 obj
<>
endobj
110 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 77 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 79 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 81 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 83 0 R/Type/Page>>
endobj
40 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 85 0 R/Type/Page>>
endobj
63 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 87 0 R/Type/Page>>
endobj
66 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 89 0 R/Type/Page>>
endobj
201 0 obj
[206 0 R]
endobj
202 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:3)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(488)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 72 714.5293 Tm
(patients with severe active rheumatoid arthritis. Bone Marrow)Tj
0 -1.25 TD
[(T)35 (ransplant 1998;22:1035-41.)]TJ
-1.3 -1.25 Td
[(8.)-550 (Breban M, Dougados M, Picard F)80 (, et al. Intensified-dose \(4 g/m)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 278.1857 697.1693 Tm
(2)Tj
8 0 0 8 280.7856 694.5293 Tm
(\))Tj
-0.00011 Tc 0.02499 Tw -26.0982 -1.25 Td
(cyclophosphamide and granulocyte colony-stimulating factor)Tj
T*
(administration for haemopoietic stem cell mobilization in refractory)Tj
T*
[(rheumatoid arthritis. )55 (Arthritis Rheum 1999;42:2275-80.)]TJ
-1.3 -1.25 Td
[(9.)-550 (Joske DJL. )55 (Autologous bone-marrow transplantation for rheumatoid)]TJ
1.3 -1.25 Td
(arthritis. Lancet 1997;350:337-8.)Tj
-1.8 -1.25 Td
[(10.)-550 (Durez P)111 (, )18 (T)70 (oungouz M, Schandene L, Lambermont, Goldman M.)]TJ
1.8 -1.25 Td
[(Remission and immune reconstitution after )18 (T)92 (-cell depleted stem cell)]TJ
T*
(transplantation for rheumatoid arthritis [letter]. Lancet)Tj
0 Tc 0 Tw T*
(1998;352:881.)Tj
-0.00011 Tc 0.02499 Tw -1.7631 -1.25 Td
[(1)37 (1.)-550 (Durez P)111 (, Ferster )55 (A, Poungouz M, et al. )55 (Autologous )18 (T)-257 (cell depleted)]TJ
1.7631 -1.25 Td
(CD34+ peripheral blood stem cell transplantation in four patients)Tj
T*
(with refractory rheumatoid arthritis and juvenile chronic arthritis)Tj
T*
[([abstract]. )55 (Arthritis Rheum 1999;42 Suppl:S77.)]TJ
-1.8 -1.25 Td
[(12.)-550 (Snowden JA, Biggs JC, Milliken ST)74 (, Fuller )55 (A, Brooks PM. )55 (A)-220 (phase)]TJ
1.8 -1.25 Td
(I/II dose escalation study of intensified cyclophosphamide and)Tj
T*
(autologous blood stem cell rescue in severe active rheumatoid)Tj
T*
[(arthritis. )55 (Arthritis Rheum 1999;42:2286-92.)]TJ
-1.8 -1.25 Td
[(13.)-550 (Burt R, Geor)18 (ganas C, Shroeder J, et al. )55 (Autologous hemopoietic)]TJ
1.8 -1.25 Td
(stem cell transplantation in refractory rheumatoid arthritis: sustained)Tj
T*
[(response in two of four patients. )55 (Arthritis Rheum 1999;42:2281-5.)]TJ
-1.8 -1.25 Td
[(14.)-550 (V)111 (erbur)18 (g RJ, Kruize )55 (AA, van den Hoogen FH, et al. High-dose)]TJ
1.8 -1.25 Td
(chemotherapy and autologous hematopoietic stem cell )Tj
T*
(transplantation in patients with rheumatoid arthritis: results of an)Tj
T*
[(open study to assess feasibility)65 (, safety)65 (, and ef)18 (ficacy)65 (. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2001;44:754-60.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(15.)-550 (Moore J, Milliken S, Ma D, Biggs J, Brooks P)111 (. Peripheral blood)]TJ
1.8 -1.25 Td
[(stem cell transplantation for rheumatoid arthritis \321 )55 (Australian )]TJ
T*
(experience. J Rheumatol 2001;28 Suppl 64:8-12.)Tj
-1.8 -1.25 Td
[(16.)-550 (Bingham SJ, Snowden J, McGonagle D, et al. )55 (Autologous stem cell)]TJ
1.8 -1.25 Td
(transplantation for rheumatoid arthritis \321 interim report of 6)Tj
T*
(patients. J Rheumatol 2001;28 Suppl 64:21-4.)Tj
-1.8 -1.25 Td
[(17.)-550 (Pavletic SZ, O\325Dell JR, Pirruccello SJ, et al. Intensive )]TJ
1.8 -1.25 Td
(immunoablation and autologous blood stem cell transplantation in)Tj
T*
[(patients with refractory rheumatoid arthritis: )18 (The University of)]TJ
T*
(Nebraska experience. J Rheumatol 2001;28 Suppl 64:13-20.)Tj
-1.8 -1.25 Td
[(18.)-550 (Pavletic SZ, Klassen L)74 (W)92 (, Pope R, et al. )18 (T)35 (reatment of relapse after)]TJ
1.8 -1.25 Td
(autologous blood stem cell transplantation for severe rheumatoid)Tj
T*
(arthritis. J Rheumatol 2001;28 Suppl 64:28-31.)Tj
31.2 50 Td
[(19.)-550 (Moore J, Brooks P)111 (, Milliken S, et al. )55 (A)-220 (pilot randomized trial)]TJ
1.8 -1.25 Td
(comparing CD34 selected versus unmanipulated haemopoietic stem)Tj
T*
[(cell transplantation for severe resistant rheumatoid arthritis. )55 (Arthritis)]TJ
0 Tc T*
(Rheum 2002;46:2301-9.)Tj
-0.00011 Tc -1.8 -1.25 Td
[(20.)-550 (Felson DT)74 (, )55 (Anderson JJ, Boers M, et al. )55 (ACR preliminary definition)]TJ
1.8 -1.25 Td
[(of improvement in rheumatoid arthritis. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1995;6:727-35.)Tj
-0.00011 Tc 0.02499 Tw -1.8 -1.25 Td
[(21.)-550 (Pinals RS, Masi )55 (A)111 (T)74 (, Larsen RA. Preliminary criteria for clinical)]TJ
1.8 -1.25 Td
[(remission in rheumatoid arthritis. )55 (Arthritis Rheum 1981;24:1308-15.)]TJ
-1.8 -1.25 Td
[(22.)-550 (Fries JF)80 (, Spitz P)111 (, Kraines RG, Holman HR. Measurement of patient)]TJ
1.8 -1.25 Td
[(outcome in arthritis. )55 (Arthritis Rheum 1980;23:137-45.)]TJ
-1.8 -1.25 Td
[(23.)-550 (van der Heide )55 (A, Remme CA, Hofman DM, Jacobs JW)92 (, Bijlsma JW)92 (.)]TJ
1.8 -1.25 Td
(Prediction of progression of radiological damage in newly )Tj
T*
[(diagnosed rheumatoid arthritis. )55 (Arthritis Rheum 1995;38:1466-75.)]TJ
-1.8 -1.25 Td
[(24.)-550 (Mottonnen )18 (T)74 (, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J,)]TJ
1.8 -1.25 Td
[(Hannonne P)111 (. Only high disease activity and positive rheumatoid)]TJ
T*
(factor indicate poor prognosis in patients with rheumatoid arthritis)Tj
T*
[(treated with \324saw-tooth\325)-201 (strategy)65 (. )55 (Ann Rheum Dis 1998;57:533-9.)]TJ
-1.8 -1.25 Td
[(25.)-550 (Anderson JJ, )18 (W)80 (ells G, )18 (V)111 (erhoeven )55 (AC, Felson DT)74 (. Factors predicting)]TJ
1.8 -1.25 Td
[(response to treatment in rheumatoid arthritis \321 )18 (The importance of)]TJ
T*
[(disease duration. )55 (Arthritis Rheum 2000;43:22-9.)]TJ
-1.8 -1.25 Td
[(26.)-550 (Ollier )18 (WER, MacGregor )55 (A. Genetic epidemiology of rheumatoid)]TJ
1.8 -1.25 Td
(disease. Br Med Bull 1995;51:267-85.)Tj
-1.8 -1.25 Td
[(27.)-550 (Salmon M, Gaston JSH. )18 (The role of )18 (T)92 (-lymphocytes in rheumatoid)]TJ
1.8 -1.25 Td
(arthritis. Br Med Bull 1995;51:332-45.)Tj
-1.8 -1.25 Td
[(28.)-550 (Euler HH, Marmont )55 (AM, Bacigalupo )55 (A, et al. Early recurrence or)]TJ
1.8 -1.25 Td
(persistence of autoimmune diseases after unmanipulated autologous)Tj
T*
(stem cell transplantation. Blood 1996;88F:3621-5.)Tj
-1.8 -1.25 Td
[(29.)-550 (Emery P)111 (, Buch M. )18 (T)35 (reating rheumatoid arthritis with tumour)]TJ
1.8 -1.25 Td
(necrosis factor alpha blockade. BMJ 2002;324:312-3.)Tj
-1.8 -1.25 Td
[(30.)-550 (Burt RK, Barr )18 (W)92 (, Oyama )37 (Y)129 (, )18 (T)35 (raynor )55 (A, Slavin S. Future strategies)]TJ
1.8 -1.25 Td
(in hematopoietic stem cell transplantation for rheumatoid arthritis. )Tj
T*
(J Rheumatol 2001;28 Suppl 64:42-8.)Tj
-1.8 -1.25 Td
[(31.)-550 (McSweeney P)111 (. Non-myeloablative allogeneic hematopoietic cell)]TJ
1.8 -1.25 Td
(transplants: any role for rheumatoid arthritis? J Rheumatol 2001;28)Tj
0 Tc T*
(Suppl 64:49-54.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
89 0 obj
<>stream
8;Z\7$#[X7%-.@PW:-fT/L8%.n@.K1"*UBk6>EgM(1r"e!g9IW&CR3FW&L0
8QSC08V3#?GH"Ua9"#bfUFp19Bs^5aZ/7!ZT,:sf8o<2eMm9`?hGH+h8K/f:-^un1
LS03N(7_aZ$=3"U%8Q)[Y!UM:;:[&g_g9#:?u%VWWkI7ob%==@H?]`+,$%2M4@TY,
hZT52\crN6Q(rf0l+f=o0),p;f9n+nd[CZo,ltLN+%7u_>dQUKXR`abn707#:B?J#
2VU.H=XXr=c5`W?$1_E]#E^nuC.a^+B>kGV3ZP!KHl/J2;\;)Sm,9ffuH@
U3Wlg9+2,h[QqQX47'EE5S)F4hQi2H;`j/fP>_@N-&mN3!aY#`nm1-u.r(@H9r$3f
UX`US3,2mWIjZ(FmM('ri/AWeo0F>NO)6uU?":fb@UJR
endstream
endobj
93 0 obj
[/Indexed/DeviceRGB 255 92 0 R]
endobj
92 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
148 0 obj
<>
endobj
113 0 obj
<>
endobj
121 0 obj
<>
endobj
133 0 obj
<>
endobj
180 0 obj
<>
endobj
116 0 obj
<>
endobj
127 0 obj
<>stream
H|TPIa$*LLR
nX"+GQf1
Q-Q|g6n]]tw_㘹xj՛\bXz9`6c%kopZ")'[RR3;gk+3AC8.8U^mj6Y/,s_|)]!VʾH+cupN)d2^Sꕺ}Ye*L!)"
]LGQ'k252:bF'Sq8}n*BЩ_0ϼ1kvGgfJ1i0,ÎayĮc,24s37K4;mv EAⅹ%iE